WO2025242589 - PHARMACEUTICAL DOSAGE FORMS FOR DEFERIPRONE AND DEFERASIROX COMBINED THERAPY
National phase entry is expected:
Publication Number
WO/2025/242589
Publication Date
27.11.2025
International Application No.
PCT/EP2025/063656
International Filing Date
19.05.2025
Title **
[English]
PHARMACEUTICAL DOSAGE FORMS FOR DEFERIPRONE AND DEFERASIROX COMBINED THERAPY
[French]
FORMES POSOLOGIQUES PHARMACEUTIQUES POUR THÉRAPIE COMBINÉE DE DÉFÉRIPRONE ET DE DÉFÉRASIROX
Applicants **
CHIESI FARMACEUTICI S.P.A.
Inventors
PERTILE, Marisa
LUZZI, Roberta
Priority Data
24177148.4
21.05.2024
EP
24214931.8
22.11.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2820 | |
| EPO | Filing, Examination, Granting | 20853 | |
| Japan | Filing, Examination, Granting | 2925 | |
| South Korea | Filing, Examination, Granting | 3666 | |
| USA | Filing, Examination, Granting | 8740 |
Total:
39,004
Contact Us
Abstract[English]
The invention relates to a pharmaceutical dosage form filled with formulations for once-a-day oral administration of deferiprone and deferasirox. Both formulations are in form of coated pellets or coated minitablets. The invention is directed to the claimed pharmaceutical dosage form for use in the treatment of diseases which cause an overload of iron.[French]
L'invention concerne une forme posologique pharmaceutique remplie de formulations pour une administration par voie orale une fois par jour de défériprone et de déférasirox. Les deux formulations se présentent sous la forme de pastilles enrobées ou de minicomprimés enrobés. L'invention concerne la forme posologique pharmaceutique revendiquée destinée à être utilisée dans le traitement de maladies qui provoquent une surcharge de fer.